Rodriguez D , Ramesh C , Henson LH , Wilmeth L , Bryant BK , Kadavakollu S , Hirsch R , Montoya J , Howell PR , George JM , Alexander D , Johnson DL , Arterburn JB , Shuster CB .

P20 RR016480 NCRR NIH HHS , P20 RR016480-08 NCRR NIH HHS , P20 RR16480 NCRR NIH HHS , Howard Hughes Medical Institute

Al-Qawasmeh, Triaryl methane derivatives as antiproliferative agents. 2004, Pubmed

Al-Qawasmeh, Triaryl methane derivatives as antiproliferative agents. 2004, Pubmed
Beer, Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. 2008, Pubmed
Behnke-Parks, Loop L5 acts as a conformational latch in the mitotic kinesin Eg5. 2011, Pubmed
Benzaquen, Clotrimazole inhibits cell proliferation in vitro and in vivo. 1995, Pubmed
Bergnes, Mitotic kinesins: prospects for antimitotic drug discovery. 2005, Pubmed
Blagden, A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. 2008, Pubmed
Blangy, Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. 1995, Pubmed
Brier, Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. 2004, Pubmed
Brier, Use of hydrogen/deuterium exchange mass spectrometry and mutagenesis as a tool to identify the binding region of inhibitors targeting the human mitotic kinesin Eg5. 2006, Pubmed
Brier, Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. 2006, Pubmed
Carol, Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. 2009, Pubmed
Carter, Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. 2009, Pubmed
Casanova, 5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. 2006, Pubmed
Cochran, ATPase mechanism of Eg5 in the absence of microtubules: insight into microtubule activation and allosteric inhibition by monastrol. 2005, Pubmed
Cochran, Monastrol inhibition of the mitotic kinesin Eg5. 2005, Pubmed
Cox, Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. 2008, Pubmed
Debonis, Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5. 2008, Pubmed
DeBonis, In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. 2004, Pubmed
Dothager, Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest. 2005, Pubmed
Duhl, Inhibitors of kinesin motor proteins--research and clinical progress. 2005, Pubmed
Funk, Development of high-throughput screens for discovery of kinesin adenosine triphosphatase modulators. 2004, Pubmed
George, Bisphenol A directly targets tubulin to disrupt spindle organization in embryonic and somatic cells. 2008, Pubmed , Echinobase
Goshima, The roles of microtubule-based motor proteins in mitosis: comprehensive RNAi analysis in the Drosophila S2 cell line. 2003, Pubmed
Hapuarachchige, Design and synthesis of a new class of membrane-permeable triazaborolopyridinium fluorescent probes. 2011, Pubmed
Haque, Monastrol, a prototype anti-cancer drug that inhibits a mitotic kinesin, induces rapid bursts of axonal outgrowth from cultured postmitotic neurons. 2004, Pubmed
Huszar, Kinesin motor proteins as targets for cancer therapy. 2009, Pubmed
Jordan, Microtubules as a target for anticancer drugs. 2004, Pubmed
Kaan, Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5. 2011, Pubmed
Kantarjian, Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. 2012, Pubmed
Kapoor, Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. 2000, Pubmed
Kathman, A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression. 2009, Pubmed
Khalid, Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. 2005, Pubmed
Kim, Allosteric drug discrimination is coupled to mechanochemical changes in the kinesin-5 motor core. 2010, Pubmed
Knight, Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP. 2008, Pubmed
Knox, A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). 2008, Pubmed
Lad, Mechanism of inhibition of human KSP by ispinesib. 2008, Pubmed
Lawrence, A standardized kinesin nomenclature. 2004, Pubmed
Lee, A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. 2008, Pubmed
Maliga, Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. 2006, Pubmed
Maliga, A pathway of structural changes produced by monastrol binding to Eg5. 2006, Pubmed
Maliga, Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. 2002, Pubmed
Marshall, Characterization of inhibitor binding to human kinesin spindle protein by site-directed mutagenesis. 2009, Pubmed
Mayer, Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. 1999, Pubmed
Mountain, The kinesin-related protein, HSET, opposes the activity of Eg5 and cross-links microtubules in the mammalian mitotic spindle. 1999, Pubmed
Nakai, K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. 2009, Pubmed
Ogo, Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors. 2007, Pubmed
Palchaudhuri, Triphenylmethylamides (TPMAs): Structure-activity relationship of compounds that induce apoptosis in melanoma cells. 2008, Pubmed
Palchaudhuri, The complex role of the triphenylmethyl motif in anticancer compounds. 2008, Pubmed
Peters, Kinesin-5 motors are required for organization of spindle microtubules in Silvetia compressa zygotes. 2006, Pubmed
Riddoch, A solid-phase labeling strategy for the preparation of technetium and rhenium bifunctional chelate complexes and associated peptide conjugates. 2006, Pubmed
Shi, Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. 2008, Pubmed
Shimizu, S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line. 2010, Pubmed
Skoufias, S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. 2006, Pubmed
Snajdrova, Clotrimazole, an antimycotic drug, inhibits the sarcoplasmic reticulum calcium pump and contractile function in heart muscle. 1998, Pubmed
Tang, Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. 2008, Pubmed
Tarby, Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series. 2006, Pubmed
Tcherniuk, Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines. 2010, Pubmed
Tunquist, Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. 2010, Pubmed
Turner, Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker. 2001, Pubmed
Zee-Cheng, Experimental antileukemic agents. Preparation and structure-activity study of S-tritylcysteine and related compounds. 1970, Pubmed
Zhang, Progress on kinesin spindle protein inhibitors as anti-cancer agents. 2008, Pubmed
Zhou, Targeting microtubules for cancer chemotherapy. 2005, Pubmed